INTRODUCTION
============

Epithelial ovarian carcinoma (EOC) accounts for the highest cancer-related mortality among gynecologic malignancies. In 2011, it was estimated that 225,500 women were diagnosed with EOC, and that 140,200 died of the disease worldwide \[[@B1]\]. Despite the fact that complete clinical remission can be achieved in approximately 80% of these patients, owing to cytoreductive surgery followed by systematic front-line chemotherapy, the majority of these clinical complete responders eventually develop recurrent disease \[[@B2]\]. Most women who relapse will be offered further chemotherapy, with the likelihood of benefit and improved survival related in part to the initial response to chemotherapy, and to the duration of the response \[[@B3]\]. Although monotherapy can improve progression-free survival even in patients with platinum-resistant disease \[[@B4]\], patients with recurrent ovarian cancer are essentially incurable. Once patients experience recurrence, they will have to endure long-term treatment with toxic side effects, anxiety, fear for their life, and various tumor-related symptoms. Accordingly, the goals of recurrent ovarian cancer treatment are to prolong survival, delay the time to progression, control disease-related symptoms, minimize treatment-related symptoms, and maintain or improve the quality of life (QoL) \[[@B5]\]. Hence, it is crucial to consider postrecurrence survival (PRS) as another indicator related to both the QoL and length of life, even though overall and progression-free survival rates have previously been used in most clinical studies. Indeed, a variety of systematic treatments, including salvage chemotherapy and/or secondary cytoreductive surgery, have been conducted to improve the overall survival (OS) and PRS \[[@B6]-[@B12]\]. However, to our knowledge, there are only a few reports regarding PRS specifically.

Patients with recurrent ovarian cancer show a wide variety of clinical outcomes that depend on many factors related to chemotherapy, such as the response to the initial treatment, duration of the response, and the number of cycles/regimen \[[@B3]\]. Our group has previously reported that when stratifying by the treatment period, the PRS has been prolonged over the last decade (≥2000) compared with prior to this period (≤1999) \[[@B13]\]. Taxane plus platinum has been widely used worldwide as first-line chemotherapy since the latter half of the 1990s. Particularly, in a platinum-sensitive setting, taxane-including salvage chemotherapy may contribute to the improvement of OS and PRS in recurrent ovarian cancer. Thus, we questioned whether the first-line chemotherapy influences the prognosis of patients with recurrent ovarian cancer, especially the PRS.

In the present study, we evaluated the survival outcomes of recurrent ovarian cancer according to the first-line chemotherapy regimen (taxane plus platinum or platinum-based regimen excluding taxane). It is well-known that EOC tumors with a clear cell or mucinous histology are some of the most aggressive and malignant tumors, because of their potential resistance to conventional platinum-based chemotherapy \[[@B14]-[@B16]\]. Thus, we also focused on the difference in survival outcomes of patients with recurrent ovarian cancer according to the histologic types (clear cell or mucinous vs. non-clear cell and non-mucinous histologies).

MATERIALS AND METHODS
=====================

1. Patients
-----------

Between 1986 and 2008, more than 1,500 cases of EOC were registered and analyzed by the Tokai Ovarian Tumor Study Group, consisting of Nagoya University Hospital and affiliated hospitals. This group has accumulated regional clinical data on malignant ovarian tumors under the central pathologic review system as a population-based study. Data were collected from medical records and clinical follow-up visits. Patients were eligible if they fulfilled the following criteria: (1) Primary laparotomy was conducted to facilitate assessment of the abdominal contents; (2) Histologic slides were reviewed under a central pathologic review system by several adequately experienced pathologists who specialize in gynecologic pathology, with no knowledge of the patients\' clinical data; (3) Recurrence or progression was diagnosed by radiologic and/or physical findings and/or an increasing CA-125 level (\>35 U/mL) suggestive of disease; (4) Patients had sufficient clinicopathological data regarding recurrence, including the date of recurrence; and if (5) Patients had sufficient clinical information on first-line chemotherapy. Patients were excluded from this study if follow-up was not possible immediately after surgery. Finally, 574 patients with recurrent ovarian cancer were enrolled in the current study. The study was approved by the ethics committee of Nagoya University. The histologic cell types were assigned according to the criteria of the World Health Organization.

2. Treatment
------------

In principle, standard primary surgical treatment consisted of hysterectomy, bilateral salpingo-oophorectomy, infracolic omentectomy, peritoneal washing, retroperitoneal lymphadenectomy, or sampling. In patients deemed too old, or in patients with severe complications, retroperitoneal lymphadenectomy was not performed. If residual tumor remained, maximal cytoreductive surgery was performed. When retroperitoneal lymphadenectomy was omitted in patients without residual tumor, the absence of enlarged lymph nodes \>1 cm in diameter was confirmed by a preoperative computed tomography (CT) scan; if present, palpable nodes were appropriately sampled. All patients were treated postoperatively with at least three cycles of platinum-based chemotherapy as a first-line treatment. We divided all patients into two groups: group A (n=261); patients who underwent taxane plus platinum, and group B (n=313); patients who underwent conventional platinum-based chemotherapy without taxanes. Details of the chemotherapy regimens in each time period have been previously described \[[@B17]\]. Briefly, patients received first-line chemotherapy as follows: CAP (cyclophosphamide, 300 mg/m^2^; adriamycin, 30 mg/m^2^; and cisplatin, 70 mg/m^2^), 1986-1989; CAP or PVB (cisplatin, 70 mg/m^2^; vinblastine, 6 mg/m^2^; and bleomycin, 12 mg/m^2^), 1989-1991; PVB or PP (carboplatin, 300 mg/m^2^ and cisplatin, 70 mg/m^2^), 1992-2000; TC (paclitaxel, 180 mg/m^2^ and carboplatin, area under the curve \[AUC\] 5), 2000-2002; and TC or DC (docetaxel, 70 mg/m^2^ and carboplatin, AUC 5), 2003 and onwards. The standard treatment for the first relapse was mainly based on intravenous salvage chemotherapy.

3. Follow-up and analysis
-------------------------

At the end of treatment, all patients underwent a strict follow-up, consisting of clinical checkups including pelvic examinations, ultrasonographic scans, CA-125 evaluations, and periodic radiologic images. Radiologic recurrence was defined as tumor recurrence based on CT, magnetic resonance imaging, positron emission tomography, and/or ultrasound, and clinical recurrence was defined as the development of ascites, elevated CA-125, or a clinically palpable mass according to the Gynecologic Cancer InterGroup criteria in principle \[[@B18]\]. OS was defined as the time between the date of surgery and the last date of follow-up or death from any cause. PRS was defined as the time interval between the date of recurrence and the last date of follow-up or death from any cause. The survival curves were created using the Kaplan-Meier method, and compared using Log-rank tests. Multivariable analysis was carried out using the Cox proportional hazard model to evaluate independent factors affecting survival. A p-value \<0.05 was considered significant.

RESULTS
=======

1. Patients characteristics
---------------------------

The patients\' characteristics are summarized in [Table 1](#T1){ref-type="table"}. The median age was 54 years (range, 14 to 84 years). The median follow-up for all patients was 30.9 months (range 2.1 to 250.2 months). Three hundred and thirteen patients (54.5%) received conventional platinum-based chemotherapy without taxanes, and 261 patients (45.5%) received taxane plus platinum chemotherapy. Patients in group A were older than those in group B (p=0.040). However, distributions of the International Federation of Gynecology and Obstetrics (FIGO) stage, histologic type, and extent of residual tumors, did not significantly differ between the two chemotherapy groups.

2. The survival of patients with recurrent ovarian cancer
---------------------------------------------------------

As shown in [Fig. 1](#F1){ref-type="fig"}, the 3-, 5-, and 7-year OS rates of all patients with recurrent ovarian cancer were 49.9, 30.4, and 21.7%, respectively. The 5-year OS rates of patients in groups A and B were 37.4 and 25.4%, respectively. The median OS rates for group A and B were 45.0 months and 30.3 months, respectively, and the patients in group B had a significantly poorer prognosis than those in group A (p\<0.001) ([Fig. 1](#F1){ref-type="fig"}). Similarly, the 3- and 5-year PRS rates of all 574 patients were 24.8% and 16.4%, respectively. [Fig. 2](#F2){ref-type="fig"} shows PRS curves stratified by each group. Median PRS rates for the two groups were as follows: group A, 23.0 months; group B, 13.0 months. The rate of PRS was significantly lower in group B compared to group A (5-year PRS; 13.2% vs. 18.4%, respectively, p\<0.001; [Fig. 2](#F2){ref-type="fig"}).

We subsequently examined whether the prognosis of patients with recurrent ovarian cancer could be stratified by the histologic features and type of chemotherapy. In patients with clear cell or mucinous histology, the OS and PRS did not significantly differ, regardless of the type of chemotherapy (OS, p=0.777; PRS, p=0.962) ([Fig. 3](#F3){ref-type="fig"}). In contrast, as shown in [Fig. 4](#F4){ref-type="fig"}, among patients with serous, endometrioid, and other histologies, the OS and PRS of group A were significantly better compared to group B (OS, p\<0.001; PRS, p\<0.001). We additionally performed univariate analyses in relation to other clinicopathological factors such as age (≤54 vs. \>54), FIGO stage (I-II vs. III-IV), and surgery based on the residual tumor (complete \[residual tumor=0\] or optimal \[residual tumor \<1 cm\] vs. suboptimal \[residual tumor ≥1 cm\] vs. unknown). In patients with clear cell or mucinous histology, there were no significant differences observed in OS and PRS between the age and FIGO stage categories. In contrast, patients who underwent complete or optimal surgery showed significantly poorer OS and PRS than those who received suboptimal surgery (data not shown). Moreover, in patients with non-clear cell and non-mucinous histologies (serous/endometrioid/others), the OS and PRS did not significantly differ between the two age categories. On the other hand, for both OS and PRS, a significantly poorer prognosis was noted in patients with complete/optimal surgery or FIGO stage III-IV tumors, compared to those with suboptimal surgery or FIGO stage I-II tumors (data not shown).

3. Multivariable analyses
-------------------------

Lastly, we performed multivariable analyses to examine whether these factors were also independent prognostic factors for the OS and PRS of the patients ([Table 2](#T2){ref-type="table"}). In patients with each histologic type (clear cell/mucinous and serous/endometrioid/others), the four aforementioned clinicopathological factors were individually entered into the Cox proportional hazard analysis. In patients with clear cell or mucinous histology, none of the factors, excluding the type of surgery (complete/optimal vs. suboptimal), significantly influenced the OS and PRS. On the other hand, among those with a non-clear cell or non-mucinous histology, the stage, surgery, and type of chemotherapy were all significant independent predictors of a poorer OS and PRS (FIGO, I-II vs. III-IV: hazard ratio \[HR\] 1.623, 95% confidence interval \[CI\] 1.154 to 2.281, p=0.005; surgery, complete/optimal vs. suboptimal: HR 1.334, 95% CI 1.039 to 1.714, p=0.024; chemotherapy, group A vs. B: HR 1.976, 95% CI 1.553 to 2,514, p\<0.001).

DISCUSSION
==========

In this study of 574 patients with recurrent ovarian cancer, we observed similar prognostic tendencies using both OS and PRS. Considering the importance of the QoL and length of life in these patients, it might be better to utilize an indicator of PRS more frequently. We showed here that, when stratifying to the front-line chemotherapy, the OS and PRS of patients with recurrent ovarian cancer who received taxane plus platinum were longer than those of patients treated with the conventional platinum-based regimen. This was consistent with the fact that retreatment with a taxane-including regimen resulted in a survival benefit compared to taxane-excluding treatment in some patients with recurrent ovarian cancer. Based on an ICON4/AGO-OVAR-2.2 randomized trial including 802 patients with platinum-sensitive recurrent ovarian cancer, paclitaxel plus platinum chemotherapy seems to improve the overall and progression-free survival compared with conventional platinum-based chemotherapy \[[@B19]\]. This longer survival may be attributable to the direct power of frontline chemotherapy *per se*, and its retreatment. However, we believe that the development of systematic treatment played a greater role in the improvement of the outcome, along with chemotherapy itself. Namely, in the treatment of recurrent ovarian cancer, a variety of cytotoxic agents, such as taxanes, liposomal doxorubicin, gemcitabine, and topotecan, are utilized with appropriate surgical management and improved palliative supportive care. Moreover, management using the treatment-free interval has been suggested for the selection of subsequent chemotherapeutic agents after recurrence. Patients who are considered to have a \"platinum-sensitive\" tumor are suitable targets for retreatment with the same platinum-based regimen.

Indeed, according to our recent report examining the long-term clinical outcomes of patients with recurrent ovarian cancer, on stratifying by the histologic types and treatment periods, the prognosis of patients with recurrent ovarian cancer was significantly improved compared to before 2000 in terms of both OS and PRS \[[@B13]\]. Nevertheless, the biological characteristics, including the sensitivity to a chemotherapeutic agent, are known to differ between histologic subtypes. In practice, we showed that the benefit in OS and PRS in all patients with recurrent ovarian cancer who underwent taxane plus platinum as a front-line chemotherapy was attributable to the improvement of survival in those with a non-clear cell or non-mucinous histology. On the other hand, in those with a clear cell or mucinous histology, the OS and PRS were not improved regardless of the type of chemotherapy. Furthermore, the current multivariable analysis revealed that the type of chemotherapy was a significant independent predictor of a poorer PRS for patients with a non-clear cell or non-mucinous histology, but not for patients with a clear cell or mucinous histology, and these results indicate that there was no prognostic progress in patients with these histologies. In fact, based on our previous investigation, the PRS of patients with clear cell or mucinous histology did not significantly differ regardless of the treatment period \[[@B13]\].

In most clinical trials in recurrent ovarian cancer, the majority of patients enrolled had a serous tumor, whereas tumors with a clear cell or mucinous histology were uncommon. Indeed, several studies have previously reported the inconsistent association between the oncologic outcome and prognosis in patients with less common histologies \[[@B16],[@B20]-[@B23]\]. Patients with clear cell or mucinous histologies have historically been treated similarly to those with other histologies, due to a lack of promising therapies for these malignancies. Nevertheless, according to recent reports from Takano et al. \[[@B24]\], less than a 10% treatment response was demonstrated in patients with recurrent ovarian clear cell carcinoma involving either a platinum-sensitive or platinum-resistant tumor. Thus, the concept of treatment free intervals *per se* may not be applicable for patients with this histology. On the other hand, according to previous reports, an earlier introduction of palliative care can lead to significant improvements in the QoL \[[@B25],[@B26]\]. Therefore, in these patients, we also consider palliative care as an essential approach to cancer care that, along with symptom control, focuses on aspects of life important to patients and their families, in an attempt to protect against, and relieve suffering.

The current study has limitations associated with all retrospective investigations. Although our study includes a comparatively large series, the non-prospective approach contains weaknesses with respect to the treatment heterogeneity, selection-bias, and a possibility of type I and II errors. In particular, the absence of a significant difference between the two chemotherapy groups in patients with a clear cell or mucinous histology may merely reflect a lack of power as a type II error. Moreover, since the current cohort underwent a multi-institutional study over a long period, the salvage chemotherapy was diverse and information on secondary cytoreductive surgery was unfortunately deficient. Complete cytoreductive surgery in patients with recurrent ovarian cancer may particularly have a survival benefit \[[@B27]\]. In this context, our examination is still preliminary and hypothesis-generating. In contrast, one of the strengths of this analysis was that all slides were reviewed from a central pathologic perspective, leading to reduced intra-observer variability in determining the histologic type, and chemotherapeutic treatments were generally carried out with the same protocol.

In conclusion, we provide an overview of, and highlight the possible association between the prognosis of patients with recurrent ovarian cancer, and representative histologic groups, stratified by the type of chemotherapy. After the emergence of taxane plus platinum, prognostic progress has been observed in patients with recurrent ovarian cancer. However, in this study, we show that the improvement was attributable only to patients with non-clear cell or non-mucinous histologies. However, while these results are still preliminary, we have presented a novel view of PRS as well as OS in a recurrent ovarian cancer cohort of 574 patients. The findings of this investigation substantiate many practical issues, and provide a strong motivation to resolve how to best confront recurrent ovarian cancer, particularly with a less common histology such as clear cell or mucinous carcinomas.
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Patient characteristics
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FIGO, International Federation of Gynecology and Obstetrics; NA, data not available.

^\*^Comparison between none or \<1 cm (optimal) vs. ≥ 1 cm (suboptimal).
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Multivariable analyses of clinicopathologic parameters in relation to overall and postrecurrence survival
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CI, confidense interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; OS, overall survival; PRS, postrecurrence survival.
